Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT04760860
PHASE1/PHASE2

Terazosin for Dementia With Lewy Bodies

Sponsor: Qiang Zhang

View on ClinicalTrials.gov

Summary

The TZ-DLB trial will be a 3:2 (active:placebo) randomized, double-blind, placebo-controlled Pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with Lewy bodies.

Official title: a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies

Key Details

Gender

All

Age Range

0 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2027-10

Completion Date

2030-12

Last Updated

2026-03-12

Healthy Volunteers

No

Interventions

DRUG

Terazosin Hydrochloride

In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.

OTHER

Placebo

In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.

Locations (1)

University of Iowa

Iowa City, Iowa, United States